Lynch syndrome is characterized by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: MLH1, MSH2, MSH6 or PMS2.
In 2007, a group of European experts published guidelines for the clinical management of Lynch syndrome.
Since then substantial new information has become available necessitating an update of the guidelines.
Dr Hans Vasen and colleagues from The Netherlands reported that in 2011 and 2012 workshops were organized in Palma de Mallorca.
A total of 35 specialists from 13 countries participated in the meetings.
|A total of 35 specialists from 13 countries participated in the meetings|
The team formulated important clinical questions.
The team team performed a systematic literature search using the Pubmed database, and manual searches of relevant articles.
During the workshops the outcome of the literature search was discussed in detail.
Dr Vasen's team commented "The guidelines described in this paper may be helpful for the appropriate management of families with Lynch syndrome."
"Prospective controlled studies should be undertaken to improve further the care of these families."